Search hospitals > Michigan > Muskegon

Cancer and Hematology Centers of Western Michigan - Norton Shores

Claim this profile
Muskegon, Michigan 49444
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
120 reported clinical trials
1 medical researcher
Photo of Cancer and Hematology Centers of Western Michigan - Norton Shores in Muskegon

Summary

Cancer and Hematology Centers of Western Michigan - Norton Shores is a medical facility located in Muskegon, Michigan. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Adenocarcinoma and other specialties. Cancer and Hematology Centers of Western Michigan - Norton Shores is involved with conducting 120 clinical trials across 277 conditions. There are 1 research doctors associated with this hospital, such as Kathleen J. Yost.

Area of expertise

1Cancer
Global Leader
Cancer and Hematology Centers of Western Michigan - Norton Shores has run 48 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Cancer and Hematology Centers of Western Michigan - Norton Shores has run 20 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Cancer and Hematology Centers of Western Michigan - Norton Shores

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Melanoma
Cutaneous Melanoma
Pancreatic Cancer
Multiple Myeloma
Gastric Cancer
Oropharyngeal Carcinoma
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Hormone Therapy with or without Radiation

for Breast Cancer

This study is evaluating whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Cancer and Hematology Centers of Western Michigan - Norton Shores?
Cancer and Hematology Centers of Western Michigan - Norton Shores is a medical facility located in Muskegon, Michigan. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Adenocarcinoma and other specialties. Cancer and Hematology Centers of Western Michigan - Norton Shores is involved with conducting 120 clinical trials across 277 conditions. There are 1 research doctors associated with this hospital, such as Kathleen J. Yost.